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1. Introduction
The challenge for the health care sector, the government, medical profession, health
care provider, as well as for health care business manager, is to continually explore ways
to ensure that the welfares of individual patients remain the utmost primacy and promote
health care equity via corporate socially responsible activities. There is an essential need
to truly embrace corporate social responsibility (CSR) and ethical principles that would
promote equal distribution of health care resources.1 Relevant CSR activities would be
achieved by making the most significant health problems in a given society the
uppermost priority of health care organizations.

2. Organizational Ethics
a) The Moral Status of Organizations
Organizational decisions are taken by the employees, with various particular roles, on
behalf of the organization to represent its mission and purpose. Health care organizations
(HCO) are granted the same official rights as individuals and are treated as legal persons
under the law. This implies that these institutions have legal obligations and moral
obligations as well. HCO are moral agents in several senses:
•

Like individuals, they have organizational goals that are detailed in their mission
statements.

•

Organizations act like people, but their decision-making processes are formed by
a group of people rather than individualistic decision.
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•

Organizations, just like persons, are normatively assessed. They have moral
responsibilities and are anticipated to meet them. Organizations are judged on
how well they treat their employees and how well they achieve their mission.2

It cannot be absolutely argued that organizations are full- fledged moral agents. The
actions of the organization depend on the individuals who collectively take decisions.
These individuals are also accountable for organizational action. They, however, act as
agents for the organization deriving their direction from the mission and objectives of the
organization. In summary, organizations are moral agents and, like individuals, can be
held morally responsible; yet, they are different than individual moral agents because
they do not literally make choices and act.3 Therefore, institutions are exposed to several
ethical expectations by the society.
b) Stakeholder Theory
This theory takes into account the interests and rights of the comprehensive range of
individuals and organizations who cooperate with and are affected by business decisionmaking. It emphasizes the role of various stakeholders in the long term and success of
the organization. This theory is important to business ethics because it recognizes many
values and moral agency on diverse levels. A stakeholder is any individual or group of
people whose role is essential to the survival and well-being of the organizations or
cooperations. Stakeholders are mostly affected by the cooperation or organization and its
activities and guide it in defining objectives and mission. Management, employees,
shareholders, customers, suppliers, society, and the community are examples of
stakeholders.4
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This theory argues that the goal of any organization or company is to prosper the firm
and all its stakeholders. It implies that profit maximization is not a problem in itself; it
only becomes an issue if managers give profit-maximizing actions a preference over
activities that promote the well-being of primary stakeholders, including the society. 5
The theory challenges the arguments that a manger’s chief obligation is to maximize
profits and encourages the firm to coordinate stakeholder interests. The father of
stakeholder theory, R. Edward Freeman, believes that the corporations and stakeholders
have reciprocal relationships in the sense they can affect each in terms of benefits and
harms and in terms of duties and harms.6

3. Corporate Social Responsibility: Past and Present
a) Background History of CSR
While CSR was broadly examined in the last forty years of the twentieth century, the
notion that business has social responsibilities was apparent at least as early as the
nineteenth century. In Britain, idealistic business managers, as the result of the Industrial
Revolution, built factory towns, such as Port Sunlight (founded by William Lever in
1888), which was planned to offer employees and their families accommodation and
other facilities when various parts of the newly industrialized towns were slums.7
CSR was mostly identical to philanthropy, and there was difficulty distinguishing
business philanthropy from individual philanthropy.8 Early examples of CSR referred to
obligations above and beyond economic and legal responsibilitie. The 1960s saw the
spread of the CSR notion when researchers started to focus on it and define it.
Philanthropy was met with improvements in terms of employee as well as customer
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relations. The following period mainly highlighted the role of management, the need to
estimate, plan, and shape CSR as well as evaluate social performance. During the 1980s,
a sequence of ethical disgraces affected the public view, and CSR topic was carried to the
public and communities. In the1990s, CSR notion was highly accepted and companies
with good reputation were known to have good CSR practices.9 Nowadays, CSR is
known as a rising business strategy that companies are integrating into their core
activities, plans, and operations. With such growing consideration, and despite some
enduring unwillingness from the management to entirely embrace the model, CSR is
predicted to further improve in strength and significance, becoming a central
management issue of the 21st Century and ultimately a part of standard business
practice.10
b) CSR: Present Day
Many factors including economic and social globalization, scientific and
technological development, and better access to information emphasized the fact that
ethical behavior and social responsibility is vital to organization’s practices. Social
responsibility should tackle and meet other stakeholders’ interests while simultaneously
increasing shareholders’ profits.11 Re-interpreting the view of social responsibility means
that an organization should not only accomplish its economic and legal requirements but
also dynamically contribute to the social good. 12
Legal regulation is an essential condition for respectable corporate social performance
but an inadequate one. Legislation and its application confirm the legality of management
decisions.13 National and international law associated with social responsibility are
already used, but law by itself is inadequate to endorse such an ethical conduct.
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Certification of social responsibility under international norms—Social Accountability
SA 8000 and ISO 26000 are international norms that plan to apply better work settings
based on the principles of the International Labor Organization, the United Nations
Convention on Children’s Rights, and the Universal Declaration of Human Rights. 14 It is
critical for companies to adhere to a legal and ethical framework regarding business then
manage and implement CSR initiatives and activities.15The World Business Council for
Sustainable Development (WBCSD), a coalition of 120 international companies, asks the
business to undertake broader duties in the social area and assert that CSR is decisively
on the universal strategy agenda.16 The International Business Leaders Forum (IBLF),
Business for Social Responsibility (BSR), and Business in the Community (BITC) are
organizations that are promoting greater consideration to CSR.17
CSR is thought of as an enduring responsibility demanding organizations to act
ethically. Simultaneously, they should support the financial strength of the organization,
which would ultimately improve the quality of life of employees, their families, and the
community.18 The number of organizations that carry out a socially responsible behavior
is greatly increasing, meaning that citizens, and investors, are deeply aware that profit
and ethical values are compatible. Embracing a socially responsible conduct can be
tactical worldwide, contributing to the competitiveness of a company and protecting its
reputation and brand image.19 CSR is achieved only if a new model of corporate
governance is put in place that uses internal mechanisms of control and takes into account
the public and stakeholders’ accountability.20
CSR is supported by theories that signify that organizational decisions and activities
influence more than just stockholders. This perspective believes that the duty of a
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manager goes beyond making wealth; it also includes guarding the welfare of the
environment, the community, and society as a whole in which the organization
operates.21 Carroll suggested a Pyramid of Corporate Responsibilities that had economic
duties at the bottom of the pyramid, then legal responsibilities, then moral
responsibilities, which meant doing what is right, just, and fair, and avoiding or
minimizing harm to stakeholders, and finally, on the peak, philanthropic responsibilities,
which refers to contributing to refining the quality of life in a community. 22

4. Corporate Social Responsibility
a) CSR Concept
There are many definitions for CSR; all imply that CSR is influential to the
achievement of a firm’s purposes, such as profit maximization, long-term success, and
survival. Davis argued for the importance of socially responsible decision-making.
Johnson (1971) affirmed that social responsibility was compulsory since businesses
needed to balance various stakeholders’ interests and benefits to confirm the
accomplishment of several goals and long-run profit maximization. In 1973, Davis
argued businesses and organizations will ultimately lose the power and legitimacy
granted by society if they do not behave socially responsible. This idea gained support
from many researchers who started to argue for a normative approach to CSR.
Researchers emphasized that organizations and companies have moral obligations and
have to meet the societal expectations, as they are similar to individual moral agents.23
For the purpose of this paper, CSR is defined as a business approach that generates
long-term shareholder value by taking up opportunities and managing risks originating
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from socially responsible decisions.24 Early subjects in CSR conceptualization
highlighted the fact that business volunteerism was important to accomplish social
responsibilities duties. Moreover, CSR was regarded as a business cost that might
adversely impact affect the bottom line. Nevertheless, the emerging pattern that visions
CSR and shareholder wealth as harmonizing goals is driven and inspired by a different
school of thought. Drucker (1984) was the first to argue that social opportunities could
be transformed into business opportunities. He suggested that businesses can turn social
problems into economic benefits.25
b) CSR and Health Care Organizations
For HCOs, the new consideration for CSR should take into consideration the global
vast poverty- related health challenges. Nowadays, society expects more from
corporations and organizations due to hard social and economic realities. They expect
business to have a responsibility to stakeholders, society, and future generations. Since
these expectations are different, the business enterprise or organization should identify,
analyze, and prioritize the stakeholder demands to establish a realistic and practical
corporate duty. The social, health, and environmental problems facing global society
today suggest that a more and different responsibility have been allocated to other actors,
including corporations.26
Many leading stakeholders in health care hold the research-based pharmaceutical
companies accountable for the deaths of millions of people living in poverty because
such companies retain their prices for life-saving medicines high. These companies
consider financial profits more important than human life. It is noteworthy to note that
many actors are responsible for social problems, and they all share a duty to contribute to
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society prospering. Duty refers to definite responsibilities stakeholders are bound to
respect and follow. Each stakeholder has a particular duty depending on its role.
However, the assigned responsibility has to be limited and definite, adapted to each
stakeholder’s resources and role. The important responsibility of any health care
organization or pharmaceutical company is to enlighten itself about its effect on society's
numerous needs and objectives and to be thoughtful and responsive to the demands of
stakeholders. Through this tactic, the business enterprise or organization will have a
practical and defined social responsibility that is based on corporate values, resources,
technical know-how, and enlightened leadership.27
There are three types of CSR:
•

Required of business by society—the "must do" aspect of social responsibility.
This aspect is required for a corporation's sustainable existence. Examples include
the delivery of products or services in good quality and at a fair price, compliance
with laws and regulations, employment at fair and living wages and in decent
working conditions, profit-making, and wise strategic decisions. For
pharmaceutical companies, which are seen as the primary drivers of globalization
and its main beneficiaries, they are highly expected to accomplish responsibilities
that go beyond what laws require- such as correcting vulnerabilities. Moreover,
they are expected to aid in donations in cases of acute emergency and perform
differential prices for patients in poor countries.28

•

Expected of business by society—the "ought to do" aspect of social
responsibility: this is less binding than the first obligation, but it equates to "good
corporate citizenship". Examples include extra-legal obligations like avoiding
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questionable practices and being fair and responsive to legitimate concerns of
fair-minded stakeholders, as well as working legitimately beyond legal
requirements where local legal conditions do not meet enlightened standards, such
as with regard to social and environmental conduct. This dimension relates to the
ten principles of the United Nations Global.29
•

Desired of business by society—the "can do" aspect of social responsibility, the
self-actualization of which justifies public praise. Examples of the "can do'
dimension include corporate philanthropy, community and neighborhood
programs, volunteerism, and donations. “Desirable" actions cover a dimension of
social responsibility that is neither required by law nor by standard industry
practice. Delivery on the "can do" norms of social responsibility will not protect a
company whose actual operations do not comply with the law or other aspects of
the "must do" dimension. However, this dimension can offer people substantial
social and other advantages. Examples include: free training opportunities using
company structure; scholarship for children in low-income groups; psychosocial
care for employees with specific diseases; Corporate philanthropy; expenditure
beyond a corporation's concrete;30 HCO and pharmaceutical companies,
possessing both financial capitals and knowledge and experience, can donate
medications for poor people or treat disadvantaged vulnerable people.31

5. Central Ethical Values and Obligations of Health Care
Organizations
a) Ethical Values of Health Care Organizations
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Health care organizations ethics has three intertwined but distinct scopes. The first is
the expression of the moral compass for the organization referred to its mission, vision,
and values. The Chief Executive Officer should also play the role of Chief Ethics Officer.
The second dimension relates to the critical ability in identifying the ethical challenges
and solving them in methodical means. The third element relates to the practical
implication and integration of organizational ethics through management process.32
On one hand, compliance relates to meeting regulatory and legal requirements and it aids
the organizations in reducing the risk of severe punishments. Such programs are
obligatory and are usually recognized by top management. On the other hand, ethics
programs are optional and dedicated to important standards and values. 33 Ethically
admirable organizations must hold a deep set of values applicable to the promotion of
health and care of the sick and must be skilled at dealing with conflicting values that arise
in health care. Organization ethics refers to organization’s attempts in defining its core
values and mission, seek the best possible resolution of struggles, and run its functions to
confirm that it acts according to the defined set of values. The scarcity of resources in the
health care sector drives organizations to set significances in a way that is both ethically
justifiable and clinically sound.
Madison Powers and Ruth Faden in their book, Social Justice, set up ethical motives
why all human beings have a right to well-being. They define the six fundamental
dimensions of well-being: health, personal security, reasoning, respect, attachment, and
self-determination. It is proposed that governments, NGOs, and business have a
synergistic responsibility to deliver these aspects. Pharmaceutical companies create
medicines and therapies to help alleviate suffering while increasing profit. 34 Yet, these

11

companies, if they are to be morally ethical according to Powers and Faden, should play
an active part to help create access to medicine for the impoverished people around the
globe. This could be achieved in many ways, including making new treatments for
neglected tropical diseases (NTDs), offering free drugs to poor communities, providing
donated goods to disadvantaged regions, offering low-priced price structures for critical
medicines, and granting transitory patents to external companies to make life-threatening
drugs. It is important to note that the health care sector cannot solve the underlying
causes of poverty, however, the social circumstances for human health are more the
accountability of global economic organizations ranging from the World Bank and IMF
to international governments who work within this international economic structure.35
Thus, a partnership of the pharmaceutical companies and hospitals with governments,
international institutions, NGOs might achieve social and health equity.36
b) Article 14: Social Responsibility and Health
The Report of the International Bioethics Committee of UNESCO on Social
Responsibility and Health has addressed this idea of social responsibility in the
framework of health care delivery proposing a new standard in hospital governance. The
scope of this responsible behavior necessitates hospitals and other healthcare
organizations to accomplish its social and market goals, based on law and general ethical
standards. The report proposes that social responsibility should be considered a moral
obligation to create organizational value.37 The originality and the significance of this
article are that it openly broadens the concept of social responsibility, applying it not only
to the private sector but also to the public sector and governments in order to fulfill the
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full recognition and deliverance of health care as a right to everyone based on universal
ethical principles.38
Julian Huxley, the first Director-General of UNESCO, stated that in order to make
science play a part in creating peace, security and human wellbeing, it was obligatory to
correlate the uses of science to values.39 This highlights the principle of social
responsibility and health, which aims at re-arranging bioethical decision-making in the
direction of crucial concerns of several countries (such as access to quality health care
and critical medicines).40 Governments aim to promote health and social development for
their people. Progress in science and technology should also increase the access level to
quality health care and essential drugs, nutrition, and water. Progress in science and
research should also be associated with a progress of living conditions and the
environment and reduction of poverty and illiteracy rates41. Despite the increase of new
medicines and technologies, there are many global health concerns. Thus, social
responsibility actions will contribute meaningfully to a decrease of inequities in health,
promote human rights, and construct social capital. However, accountability and
commitment and the consistent performance of professional responsibilities in the chase
of social goods are always major concerns.42
Some recent international efforts to meet the needs of the unfortunate include
improved health, which also was included in the eight UN Millennium Development
Goals (MDG). This includes halving poverty, halting the spread of HIV and AIDS, and
offering worldwide primary education. The UN concrete action plan emphasized the fact
that extreme poverty is indicative of a globe of insecurity because poverty, inequality,
and disease are some of the main grounds for violent struggle and civil war. The
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Millennium project assumes that the health care sector, including hospitals and the
pharmaceutical industry, already has the technology and know-how to solve the majority
of the problems faced in poor and developing countries. The goal was to achieve the
following eight goals by the year 2015:
• Eradicate extreme poverty and hunger.
• Achieve universal primary education.
• Promote gender equality and empower women.
• Reduce child mortality.
• Improve maternal health.
• Combat HIV and AIDS, malaria and other diseases.43
Development organizations have confronted the pharmaceutical industry to increase
its efforts to tackle the health disaster affecting developing countries. They reflect that a
socially responsible company should design, plan, and implement policies on access to
treatment for developing countries which include the five significances of pricing, patent,
joint public-private initiatives, research and development, and the appropriate use of
drugs. They state that critical challenges continue, chiefly the issue of pricing. Recently,
new projects of pharmaceutical companies have a purely charitable characteristic that
will not generate profits. Examples include the new Institute for Tropical Diseases in
Singapore for the discovery of drugs for HIV and AIDS and other prevalent diseases.
These companies should make alliances with public, private, NGOs, international
organizations and civil society to address the elements of health in a globalized world
through health research and progress.44

6. Ethical Principles
a) Principle of Justice
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Thomas Pogge elaborates on the moral duty of western societies and companies to
deliver system transformation in order to alleviate some of the world’s prevalent human
grief. In his book, World Poverty and Human Rights, the comments on Articles 25 and
28 found in the United Nations Declaration on Human Rights: Everyone has the right to a
standard of living satisfactory for both the health and well-being of himself and of his
family, including food, clothing, housing, and medical care.45 Pogge then clarifies an
intuitive notion examining the current globalization and interconnections that necessitate
universal justice principles in which everyone should accept and share. Therefore, social
justice includes the human right to health based on the idea that health is a universal
human right; there must be worldwide access to medicines.46 Hence, pharmaceutical
companies and healthcare organizations have a moral responsibility to provide access to
medicine for those who cannot afford them while achieving sustainable business ends.47
Justice explains how social burdens and benefits should be distributed. The
egalitarian theories state that people should receive an equal distribution of health care.48
Based on John Rawl’s principle of Justice, the fair opportunity is vital to justice in the
health care field. This implies that each person, regardless of his/ her social status, should
have equal access to a sufficient level of health care. There should be a right to a decent
minimum49 of health care: basic health care and other health- related resources.50
b) Principle of Beneficence
In addition to justice principle, pharmaceutical companies and HCOs have an
obligation to follow the principle of beneficence. In their Principles of Biomedical
Ethics, Beauchamp and Childress describe beneficence as not simply kindness or charity,
but a real obligation to support others and further their genuine benefits. Beneficence

15

states that one should prevent harm, remove harm, and promote good.51 It is important to
note that there is an embedded beneficence assumption in all health care professions;
health education and vaccination programs. HCOs have a moral responsibility to conduct
research into medicines that can help those in disadvantaged regions, not just profit
driving medicine for Western conditions or lifestyle medications.52 Active social
responsibility requires hospitals and others healthcare organization to do something
beneficial (out of beneficence duties) and not only abiding by the law or to broad ethical
principles. This implies that the interests and values of all stakeholders are taken into
concern.53

7. Common Good
a) Pharmaceutical Corporations & Health Care Organizations
Pharmaceutical corporations and HCOs contribute to the common good. With their
goods and services, they make different types of value added for society. For instance,
current medicines and therapies, aid in reducing death rates and preventing/curing
diseases. Therefore, it is argued that successful HCOs increase the quality of life of the
sick, minimize costly hospitalization through researching, manufacture, and distribute
drugs of high social benefits.54 HCOs should pursue their ends by contributing to their
society. They own the know-how, vast resources, expertise, and management talent to
solve social problems that they fully comprehend both in the developing world and in
economically deprived communities. Creating shared value in practice by following a
strategic approach to CSR, Porter argues that such strategic CSR efforts
are fundamental to a company’s profitability, success, and competitive position.55
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Therefore, HCOs with their embedded ethical values combined with their knowledge and
resources should focus their CSR activities on solving health related issues in local and
international communities.
Clear and comprehensible efforts by individual actors, governments, donors, NGOs,
and the private sector are required to act based on each party’s skills, techniques,
knowledge, and assets. Thus, social corporate responsibility is also articulated by the
readiness of the health care organization to cooperate with other parties. The
pharmaceutical companies and HCO have an end that is achieved through its normal
business activities like research, development, manufacturing, and selling pharmaceutical
compounds to avoid premature mortality, to treat or lessen diseases, to avoid or shorten
hospitalization, and to contribute to the quality of life of sick people.56
The pharmaceutical industry and hospitals are heavily regulated, on national as well
as international levels.57 This triggers much exacerbation and financial stress.58 In the
field of health care, the ethical and socially conscious behaviors are both the community
and professions' anticipation. CSR in the health care sector is different from CSR in other
businesses because medicine and medical care are vital for the good being of humanity.59
Poor individuals cannot afford expensive medications due to the market and patent
requirements, the absence of generics, or affordable changes to patented medicines. This
truth has become intolerable in the society’s eyes. In numerous polls, U.S. consumers
rate the pharmaceutical industry as one of the most unethical businesses.60
The health care sector, in general, is a sector where the thoughts of corporate
commitment, liability towards patients, ethical performance and an overall responsibility
towards society are universal. David R Brennan, CEO of Astra Zeneca says,
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accountability is integrated into the strategy of pharmaceutical companies because of it
significant to sustained success.61 In illustrating pharmaceutical CSR, Heal suggests
programs run by the health care sector to respond to issues related to making drugs
accessible at reduced prices to impoverished populations.62All the top 20 pharmaceutical
companies have developed robust CSR initiatives and many have fundamental CSR
teams in place. Most importantly, the pharmaceutical industry and hospitals have the
technical know-how in medicine development and health care services, they have the
ethical commitments of beneficence and justice to provide better development and access
to medicines for underprivileged societies. CSR meets stakeholders’ demand, objectives
of health care institutions, and universal ethics requirements – help lessen human
suffering and improve the lives of people.63
In health care, CSR means that there is an ethical obligation that requires hospitals
and other organizations to do something beneficial to health- related issues such as
delivering quality health care to everyone who is titled to it. Integrating social
responsibility strategic planning and daily activities require time and effort by the
management professionals of HCOs.64 Pharmaceutical companies and hospitals should
tackle and meet the needs of various stakeholders and strategically focus on some.
b) CSR and Health Care
In the health care setting, a set of values should be followed such as equity in access
to health care, universal coverage, and efficient resource allocation. Therefore, the
implementation of a socially responsible behavior could be a vital step for a hospital to
expand its competitiveness and to protect its external image. There should be a serious
consideration for all stakeholders including the public and society at large: patients,
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patient associations, NGOs, the environment, healthcare professionals, healthcare payers
and policy makers, the government and regulatory groups.65 For example, a socially
responsible pharmaceutical company or hospital should investigate and find which way
to treat or carefully discard a waste product that may pollute the environment.66
Klaus Leisinger of Novartis states that the duty of the pharmaceutical company in an
international economy is to research, develop, and manufacture groundbreaking
medicines that make a transformation to sick people’s quality of life, and it is their duty
to do so in a profitable way. No other societal actor assumes this responsibility.
Nevertheless, several pharmaceutical companies recognize a moral duty to do more,
whenever probable, to aid in lessening health problems of poor individuals all over the
world.67 Small and Medium Enterprises (SMEs) in the health care sector usually adopt
different CSR practices when compared with large corporations because they do not have
the resources.68 However, SMEs should also pursue CSR activates in order to become
and remain successful locally as well as in the international economy.69 Companies report
their CSR practices to be accountable and transparent, in terms of corporate governance
as well as environmental, social and financial sustainability.70
Having a vigorous CSR program can help HCOs attract and maintain key talent.
Companies and hospitals will have better social perception and community engagement.
Surveys indicate that people not only desire to work for socially responsible firms, but
may essentially give up a proportion of salary to do so. For instance: A 2009 Kelly
Services Survey questioned around 100,000 people in 34 countries around the world.
They found 88 % of respondents are more probable to want to work for a company that is
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considered ethically and socially responsible. 56% say that in deciding where to work, an
organization’s ethical status for ethical conduct is very significant.71
Michael Porter and Mark Kramer’s view recommend companies to wisely select the
social subjects they aim to solve, especially the ones that interconnect with their
professional, proficiency, management talent, and know-how, arguing that corporations
which choose social issues based on their expertise will have a greater impact on the
social good.72 Williams and Aguilera (2008), in their comparative assessment of CSR,
report verification in the literature regarding the impact that an occupation or an industry
has on the type of CSR firm implements.73

8. Corporate Social Responsibility and Competitive Advantage
a) Examples of CSR
Nonprofit hospitals have some responsibility for contributing to the general welfare
of the community, as required by the Internal Revenue Service (IRS). Services and
resources of nonprofit hospitals that are utilized to the advantage of groups or individuals
who are not members of the plan itself are called community benefits. It is argued that
community benefits form a vital part of the ethical obligations of HCOs. Many hospitals
were established based on a charitable objective to serve the poor, and there is a long
tradition of health-care institutions offering benefits to the surrounding community.
Moreover, American hospitals have frequently provided free care and immunizations for
the uninsured. In some states, community benefit system turned to be a codified effort
rather than a voluntarily one via state laws necessitating HCOs to have shown concrete
plans for community benefits. Moreover, it is argued that generous contributions to the
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neighboring communities are a central obligation of all businesses. The pharmaceutical
industry could reinterpret the notion of social responsibility by acknowledging the access
of vulnerable populations to lifesaving medicines. Developing and enriching the local
communities are as essential as profit maximization. Eli Lilly is one of the largest
charitable foundations in the United States.74
The pharmaceutical industry could reinterpret the notion of social responsibility
by acknowledging the access of vulnerable populations to lifesaving medicines.
Examples of CSR activities include offering drugs to disadvantaged populations,
providing preferential pricing in the world poorest countries in an effort to aid combating
diseases such as AIDS and malaria, supplying vaccines to international NGOs or UN
agencies at better prices.75 Moreover, corporations should address the health and safety of
employees at work from possibly toxic processes and products. For instance, hospitals
should offer increased health and safety protection for technicians while working with
radioactive substances in particular oncology treatment manufacturing procedures.76
Other examples include: building LEED standard Green buildings, adopting
environmentally friend practices such as energy saving processes and packaging
reduction, 77 conserving water, and protecting the supply of clean potable water to the
surrounding communities.78
Philanthropy based CSR activities exemplify the pharmaceutical industry. The
main philanthropic role should be recognized to the pharmaceutical industry is its
entitlement to improve human life and offer treatment for diseases.79 Moreover,
pharmaceutical companies often set up foundations in order to support, educate and better
tackle a disease for which they offer a cure. For example, a company providing anti-
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retroviral drugs would establish a foundation that focuses on AIDS education in Africa.
Furthermore, they also deliver humanitarian action and support to various causes, often in
association to a product they deliver, or to help a community they work with, or a nation
where they carry out their production process or conduct clinical research.80Additionally,
the pharmaceutical companies usually fund research grants to students, universities, and
educational organizations because the pharmaceutical industry is very much reliant on
research and on the development of science through research.81
b) The Link Between Competitive Advantage and Corporate Social
Responsibility
Strategic CSR initiatives start with a strong strategic grounding to connection an
organization’s values to investments in social issues that can reinforce the organization’s
competitiveness. The CSR of HCOs and pharmaceutical companies should create a
balance between their responsibilities to add value to society and the growth of the
enterprises. 82 Strategic CSR can be a source of opportunity and competitive advantage
rather than a cost to the health organization and more than a moral obligation. Achieving
both social and economic interest for the organization demands to look beyond
community anticipations to opportunities. Strategic CSR should integrate society,
business, and ethical values. It necessitates the corporation to act differently from
competitors and reap the benefits of shared value by capitalizing in social issues that
reinforce company’s competitiveness. Characteristically, the more closely tied the CSR to
the company’s business, the greater the opportunity to leverage the ﬁrm’s resources and
beneﬁt society. The most strategic CSR occurs when the cooperation adds a social
element to its value preposition, and this provides a new edge in competitive positioning.
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This is essentially important especially in an era where exposure to liability, consumers’
awareness of social problems, and government regulations are all continually
increasing.83 These attitudes must change if companies want to leverage the social
dimension of corporate strategy. To choose the right options for CSR, managers of HCOs
have to be selective and construct practical and focused social initiatives and integrate
those within their core strategies.

9. Managers of Health Care Corporations
a) Virtue Ethics of Managers and Leaders at Health Care Organizations
Professional ethics, such as in healthcare, is an application of virtue ethics. This kind
of ethics focuses on the moral agent and not on the results of actions taken by the moral
agent. Virtue ethics lists good judgment as a fundamental characteristic of the moral
agent. “Practical reasoning”, as Aristotle says, is a requirement for mental virtues, and
this includes several virtues such as vision, experience, and other critical analysis skills.
High moral standards of employees would provide organization’s excellence and decent
ethical climate.84 The good character of honesty, compassion, trustworthiness, and
devotion of high-level managers is an essential requirement for excellent ethical practice.
However, this is not sufficient.
Enterprises with enlightened leadership should do more than just the minimum
obligation described by “the must” dimension in view of the global social problems of
our times. The health care organization has to entirely realize the difficult social issues,
then investigate methods to do good. Enlightened leaders who own sufficient courage and
imagination, will show the right signal through an organization and into the broader
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society. This will achieve the expectations of the society and achieve the long-term
interests of the organization.85 These leaders must integrate CSR into the cooperation’s
strategy through the understanding of the competitive market environment, the
connection with the corporation goals and strengths. This is critical to achieving the longterm goals of the organization and achieving better financial performance.86 Thus, CSR
should be linked strongly to organizations strategic planning and monitoring process.
This is more likely to happen if the institution has enlightened leadership combined with
virtue ethics.
b) Managers’ Role in Undergoing Corporate Social Responsibility Activities
The healthcare industry is significantly regulated, but the continuing request for it to
be socially responsible and ethically oriented is definite. It follows that a new
organizational culture is considered crucial to overcoming the market failures that can
appear in health care sector. 87 Public inquiry of business activities has boosted over the
last years, causing more deliberation to be placed on social contribution, social
responsibility, and the ethical performance of managers and directors. This necessitates
health care managers to fully comprehend the conceptions around CSR.88
HCOs face new encounters in recent societies. The deficiency of economic
sustainability of most health care systems guided to the introduction of the innovative
public management to certify the existence of the welfare state.89 Due to high levels of
anxiety and poverty, the criticism against globalization, increasing acknowledgment of
the failure of governments to resolve many social problems, and distrust of giant
businesses, there is mounting pressure on business managers and their companies to
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deliver broader social value. This necessitates successful management skills and
applicable use of stakeholder engagement.90
The health care industry is in a remarkable position because it supplies both the
entrepreneurial power and the skill crucial in encouraging economic development.
Nevertheless, it can often be publicly disregarded if profit maximization is noticed to be
the leading target. When debatable settings happen in an organization, the moral
character of management who take decisions can become the heart of speculation.91
Patrick Maclagan considers the debate on the ethical or non-ethical character of the
organization challenging, as these features must apply to the behavior of the members
working at the organization or company. Consequently, the emphasis should be on its
members, their personal values, actions, and ethical choices.92 The formal
implementation of CSR by corporations could be connected with the altering personal
values of managers.93 This implies that key individuals will be involved in articulating
and applying companies' CSR policy.94 Managers’ personal beliefs and values are
important, and should not be constrained by the values underlying the system in which
they operate.95
In HCOs, inaccuracies in management plans and poor leadership judgments can
influence all stakeholders and shareholders because actions could possibly form lifethreatening consequences. Health care managers, in essence, form the structure and
managerial support that makes the day-to-day activities of health care attainable. They
also tend to form the ethical norms for corporations. Thus, they must have a broad
understanding of a number of business values and ethical principles. They also need to
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acknowledge their dual role of serving the patients and communities and making a profit,
as this is a significant managerial capability.96
Therefore, health care managers need ethical training as a meaningful part of their
professional position.97 Ethical counseling may become fundamental in achieving ethical
capability and developing capacities for good success.98 The manager’s responsibility is
considered as a crucial one. The manager has the mission of bringing things together; of
making them work together, of shaping opinions and leading all action.99 However,
several factors make leadership decisions and actions morally challenged including
increased presence of managed care and an aging population predestined to demand
higher levels of health care than.100

10. Conclusion
CSR in health care applied to hospitals and pharmaceutical companies should
promote shared values and common ethical principles in new patterns of hospital
governance.101In the health care context, social responsibility has a broader field of
involvement including issues related to human rights, gender equality, child labor, and
the environment. The health care sector is rigorously anticipated to behave ethically and
deliver treatments for all individuals. As such, it is under very tight pressures from
policymakers, NGOs, media, and the public at large, especially that it has become very
competitive. The importance of CSR is now well recognized in the health care sector.102
In conclusion, CSR and organizational ethics are essential to regain vanished confidence
of the local and international communities and win back the admiration of skeptical
patients and doubting communities. Therefore, HCOs have to have a renewed
commitment to ethics.103 It is important to note that benchmarking HCOs on their CSR
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performance forms inter-business rivalry, which in turn improve CSR and leads to actual
access to medicine practices.104
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